TradeFlare's AI research teams analysed ACLX on 5 market nights between April 27, 2026 and May 19, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| May 19, 2026 | HOLD | $115.07 | — / — | not yet | not yet | Successful completion of Gilead's acquisition of Arcellx. |
| May 18, 2026 | HOLD | $115.07 | — / — | not yet | not yet | Successful completion of Gilead's acquisition of Arcellx. |
| April 29, 2026 | BUY | $115.07 | — / — | not yet | not yet | Pending acquisition by Gilead Sciences provides significant validation and a clear exit for shareholders. |
| April 28, 2026 | BUY | $115.07 | — / — | not yet | not yet | Gilead Sciences' pending acquisition of Arcellx for $7.8 billion. |
| April 27, 2026 | BUY | $115.03 | — / — | not yet | not yet | Gilead Sciences acquisition provides a significant de-risking event and price floor. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.